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Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): 
updated efficacy results from a randomised, double-blind, phase 3 trial 
 
Summary 
 
background 
 
The combination of cobimetinib with vemurafenib improves progression-free survival compared 
with placebo and vemurafenib in previously untreated patients with BRAFV600-mutant advanced 
melanoma, as previously reported in the coBRIM study. In this Article, we report updated efficacy 
results, including overall survival and safety after longer follow-up, and selected biomarker 
correlative studies. 
 
Methods 
 
In this double-blind, randomised, placebo-controlled, multicentre study, adult patients (aged ≥18 
years) with histologically confirmed BRAFV600 mutation-positive unresectable stage IIIC or stage IV 
melanoma were randomly assigned (1:1) using an interactive response system to receive 
cobimetinib (60 mg once daily for 21 days followed by a 7-day rest period in each 28-day cycle) or 
placebo, in combination with oral vemurafenib (960 mg twice daily). Progression-free and overall 
survival were primary and secondary endpoints, respectively; all analyses were done on the 
intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01689519, 
and is ongoing but no longer recruiting participants. 
 
Findings 
 
Between Jan 8, 2013, and Jan 31, 2014, 495 eligible adult patients were enrolled and randomly 
assigned to the cobimetinib plus vemurafenib group (n=247) or placebo plus vemurafenib group 
(n=248). At a median follow-up of 14·2 months (IQR 8·5–17·3), the updated investigator-assessed 
median progression-free survival was 12·3 months (95% CI 9·5–13·4) for cobimetinib and 
vemurafenib versus 7·2 months (5·6–7·5) for placebo and vemurafenib (HR 0·58 [95% CI 0·46–0·72], 
p<0·0001). The final analysis for overall survival occurred when 255 (52%) patients had died (Aug 28, 
2015). Median overall survival was 22·3 months (95% CI 20·3–not estimable) for cobimetinib and 
vemurafenib versus 17·4 months (95% CI 15·0–19·8) for placebo and vemurafenib (HR 0·70, 95% CI 
0·55–0·90; p=0·005). The safety profile for cobimetinib and vemurafenib was tolerable and 
manageable, and no new safety signals were observed with longer follow-up. The most common 
grade 3–4 adverse events occurring at a higher frequency in patients in the cobimetinib and 
vemurafenib group compared with the vemurafenib group were γ-glutamyl transferase increase (36 
[15%] in the cobimetinib and vemurafenib group vs 25 [10%] in the placebo and vemurafenib group), 
blood creatine phosphokinase increase (30 [12%] vs one [<1%]), and alanine transaminase increase 
(28 [11%] vs 15 [6%]). Serious adverse events occurred in 92 patients (37%) in the cobimetinib and 
vemurafenib group and 69 patients (28%) in the vemurafenib group. Pyrexia (six patients [2%]) and 
dehydration (five patients [2%]) were the most common serious adverse events reported in the 
cobimetinib and vemurafenib group. A total of 259 patients have died: 117 (47%) in the cobimetinib 
and vemurafenib group and 142 (58%) in the vemurafenib group. The primary cause of death was 
disease progression in most patients: 109 (93%) of 117 in the cobimetinib and vemurafenib group 
and 133 (94%) of 142 in the vemurafenib group. 
 
Interpretation 
 
These data confirm the clinical benefit of cobimetinib combined with vemurafenib and support the 
use of the combination as a standard first-line approach to improve survival in patients with 
advanced BRAFV600-mutant melanoma. 
 
 
Funding 
 
F Hoffmann-La Roche–Genentech. 
 
Introduction 
Around 40% of cutaneous melanomas harbour mutations in the BRAF gene, resulting in constitutive 
activation of the mitogen-activated protein kinase (MAPK) pathway. 1 ;  2 The treatment of 
advanced BRAF-mutant melanoma has been revolutionised by the introduction of new therapeutic 
agents such as the BRAF inhibitors vemurafenib or dabrafenib. These drugs have improved outcomes 
for patients with advanced BRAFV600-mutant melanoma, with high proportions of patients 
achieving a tumour response and improved progression-free and overall survival compared with 
cytotoxic chemotherapy. 3; 4; 5 ;  6 Acquired resistance to BRAF inhibitor monotherapy is the most 
common cause of treatment failure, limiting median progression-free survival duration to around 6 
months. 3 ;  4 Although a diverse range of resistance mechanisms has been suggested, most 
mechanisms of resistance involve reactivation of the MAPK pathway mediated through MEK. 7; 8; 9; 
10 ;  11 
 
Research in context 
 
Evidence before this study 
 
We searched PubMed up until Sept 30, 2015, with the terms “clinical trials”, “advanced melanoma”, 
“BRAF inhibitor”, and “MEK inhibitor”. We also searched conference abstracts from the American 
Society of Clinical Oncology and the European Society of Medical Oncology with the same terms. The 
results showed that, in addition to the combination of vemurafenib and cobimetinib, BRAF and MEK 
inhibitor combinations of dabrafenib and trametinib, LGX818 and MEK162 (encorafenib and 
binimetinib), have been or are being assessed in patients with advanced BRAFV600-mutant 
melanoma. Data from two phase 3 studies have shown a benefit for the trametinib and dabrafenib 
combination, whereas other combinations resulted in promising activity in early-phase trials. 
 
Added value of this study 
 
We report the protocol-specified overall survival analysis of a double-blind, multicentre, placebo-
controlled phase 3 study assessing the efficacy and safety of cobimetinib and vemurafenib compared 
with placebo and vemurafenib in previously untreated patients with BRAFV600 mutation-positive 
unresectable stage IIIC or IV melanoma. Effectiveness of the combination of cobimetinib and 
vemurafenib was superior to that of vemurafenib plus placebo for all efficacy endpoints and across a 
wide range of patient baseline characteristics, including in patients with normal baseline lactate 
dehydrogenase concentrations. To our knowledge, this is the first phase 3 comparative trial to do 
biomarker analyses to study the effect of baseline values of Ki67, pERK, and pS6 on median overall 
survival in both treatment groups. 
 
Implications of all the available evidence 
 
These data confirm the clear and definitive clinical benefit of the addition of cobimetinib to 
vemurafenib in patients with advanced BRAFV600-mutant melanoma and support the use of the 
combination as a standard targeted therapy for first-line treatment in this population. 
 
Combined BRAF and MEK inhibition enables greater inhibition of the MAPK pathway, and 
combination therapy with cobimetinib (a MEK inhibitor) and vemurafenib (a BRAF inhibitor) has 
resulted in clinical benefit.12 ;  13 The randomised, double-blind, phase 3 coBRIM study13 compared 
the combination of cobimetinib and vemurafenib versus placebo and vemurafenib in previously 
untreated patients with advanced melanoma harbouring BRAFV600 mutations. In the primary 
analysis, with a median follow-up of 7·3 months (range 0·5–16·5), cobimetinib and vemurafenib 
significantly improved progression-free survival compared with vemurafenib alone (median 9·9 
months [95% CI 9·0–not estimable] vs 6·2 months [5·6–7·4], hazard ratio [HR] 0·51 [0·39–0·68]; 
p<0·0001). Improvement in progression-free survival was recorded in every clinical subgroup 
assessed, including patients with disease characteristics recognised as poor prognostic factors: 
notably, increased lactate dehydrogenase (LDH) concentrations 14 and stage M1c disease. 14 ;  15 
The proportion of patients achieving an objective response was also significantly greater in the 
combination therapy group compared with the vemurafenib plus placebo group (68% with 
cobimetinib and vemurafenib vs 45% with vemurafenib plus placebo; p<0·0001). 13 Another BRAF 
inhibitor and MEK inhibitor combination—dabrafenib and trametinib—has resulted in efficacy 
similar to that of the combination of cobimetinib and vemurafenib with respect to several efficacy 
measures, including proportion of patients achieving an overall response, progression-free survival, 
and overall survival, compared with either dabrafenib 16 ;  17 or vemurafenib18 as monotherapy in 
phase 3 trials in advanced melanoma. 
 
In this Article, we report the results of an updated progression-free survival analysis and the final 
overall survival analysis for the coBRIM trial. Additionally, we report the results of exploratory 
analyses correlating molecular markers of MAPK and PI3K pathway activation in pre-treatment 
tumour samples with overall survival. 
 
Methods 
Study design and participants 
 
coBRIM is an ongoing double-blind, multicentre, placebo-controlled, phase 3 study assessing the 
efficacy and safety of the combination of cobimetinib and vemurafenib, compared with placebo and 
vemurafenib, in previously untreated patients with BRAFV600 mutation-positive unresectable stage 
IIIC or stage IV melanoma. The study is being done at 135 clinical sites in 19 countries: the USA, 
Australia, New Zealand, Israel, Canada, and 14 countries in Europe (including Russia). The complete 
methods of the study have previously been published and the protocol is available online.13 
 
Eligible patients were aged 18 years and older with histologically confirmed unresectable stage IIIC 
or stage IV melanoma harbouring a BRAFV600 mutation detected with the use of a real-time PCR 
assay (cobas 4800 BRAFV600 Mutation Test [Roche Molecular Systems, Branchburg, NJ, USA]); 
measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.119 
assessed by computed tomography; Eastern Cooperative Oncology Group (ECOG) performance 
status of 0 or 1; and adequate haematological, hepatic, renal, and cardiac function. Life expectancy 
of eligible patients was at least 12 weeks. The cobas 4800 BRAFV600 Mutation Test has been 
approved by the US Food and Drug Administration (FDA) and the results were confirmed by 
subsequent deep sequencing. Patients with previously treated brain metastases were eligible if they 
had a history of stable disease for at least 3 weeks. 
 
This trial is being done according to the provisions of the Declaration of Helsinki and its amendments 
and relevant Good Clinical Practice guidelines after approval by the local institutional review board, 
independent ethics committee, or research ethics board of all participating study sites. All study 
participants provided written informed consent. An independent data and safety monitoring 
committee did regular reviews and evaluations of safety data. 
 
 
 
Randomisation and masking 
 
Enrolled patients were randomly assigned 1:1 using a stratified permuted block randomisation 
scheme via an interactive response system (Perceptive Informatics [now Parexel International], 
Deerfield, IL, USA). Patients were stratified according to the American Joint Committee on Cancer 
stage (unresectable stage IIIc, M1a, and M1b vs stage M1c) and by geographical region (North 
America vs Europe vs Australia/New Zealand/other). The investigators, patients, and sponsor were 
masked to treatment assignment. 
 
Procedures 
 
Patients received either oral cobimetinib (60 mg once daily for 21 days followed by a 7-day rest 
period in each 28-day cycle) or placebo, in combination with oral vemurafenib (960 mg twice daily). 
Treatment continued until withdrawal of consent, the occurrence of unacceptable adverse events, 
or disease progression. Continuation of study treatment after disease progression or crossover to 
the alternate treatment was not allowed. Modification of the cobimetinib or vemurafenib dose was 
allowed for management of adverse events, with guidelines for events of prespecified type and 
grade (see protocol). Up to two dose-level reductions were allowed: for vemurafenib, reduction to 
720 mg twice daily or to 480 mg twice daily; for cobimetinib, reduction to 40 mg once daily or to 20 
mg once daily. Dose reduction of each study drug was independent of the other study drug. Dose re-
escalation was not allowed. 
 
Tumour assessments were done with CT scans at baseline and every 8 weeks thereafter. 
Haematology, chemistry, and liver laboratory tests were done at baseline, on days 1 and 15 of cycles 
1–6, then on day 1 of subsequent cycles. Patient-reported quality of life outcomes were measured at 
baseline, days 1 and 15 of cycles 1 and 2, and day 1 of every other cycle thereafter (28-day cycles) 
until patient withdrawal or end of study. An independent data and safety monitoring committee 
regularly reviewed and evaluated the safety data. 
 
Baseline expression of proteins Ki67 (#790-4286, Ventana Medical Systems Inc, Tucson, AZ, USA), 
pERK T202/Y204 (#4370, Cell Signaling Technology Inc, Danvers, MA, USA), and pS6 S235/236 
(#4858, Cell Signaling Technology Inc) was assessed at a central laboratory (Histogenex, Antwerp, 
Belgium) with immunohistochemistry. Ki67 expression was quantified as the percentage of tumour 
nuclei that were positive for Ki67. For assessment of pERK and pS6, staining intensity (on a scale 
from 0–3) and staining percentage were quantified in the cytoplasmic compartment, and a 
histoscore (H-score, on a scale from 0–300) was calculated.20 Other biomarker expression levels 
were assessed on-treatment or at progression only for patients who consented to undergo optional 
biopsy at these prespecified timepoints. 
 
Outcomes 
 
The primary endpoint was progression-free survival as assessed by the investigator, according to 
RECIST version 1.1.15 Progression-free survival was defined as the time between the date of 
randomisation and the date of the first documented event of disease progression or death, 
whichever occurred first. Secondary endpoints were overall survival, confirmed objective response 
(defined as a complete or partial response) according to RECIST version 1.1, response duration, 
progression-free survival assessed by an independent review facility, health-related quality of life as 
assessed by the European Organisation for Research and Cancer (EORTC) Quality of Life 
Questionnaire Core 30 (QLQ-C30),21 and safety. Prespecified biomarker analyses were exploratory. 
 
 
 
Statistical analysis 
 
The primary analysis of progression-free survival has previously been reported.13 We estimated that 
206 progression events would provide at least 95% power to detect a hazard ratio for death or 
progression of 0·55, with a two-sided α of 0·05 (an increase in median progression-free survival from 
6 months for placebo and vemurafenib to 11 months for cobimetinib and vemurafenib). The 
prespecified number of progression events (n=206) was reached in May, 2014, and results of the 
primary analysis for progression-free survival were reported after a median follow-up of 7·3 months 
(range 0·5–16·5).13 In this Article, we present the results of an updated progression-free survival 
analysis with a longer follow-up (median follow-up 14·2 months [IQR 8·5–17·3]) with the data cutoff 
date of Jan 16, 2015, which was around 1 year after the final patient was enrolled into the study. 
 
For the overall survival analysis, we estimated that 250 survival events would provide 80% power to 
detect a hazard ratio for death of 0·70 (improvement in median overall survival from 15 months in 
the placebo and vemurafenib group to 21·4 months in the cobimetinib and vemurafenib group) with 
a two-sided α of 0·05. The type I error rate for the overall survival analysis was controlled at the 0·05 
level by use of the Lan-DeMets implementation of the O'Brien-Fleming use function. We did the 
interim analysis for overall survival at the time of the primary analysis of progression-free survival, 
and the estimate of overall survival was not significant.13 85 patients had died at the time of the 
interim overall survival analysis: 34 in the cobimetinib and vemurafenib group and 51 in the placebo 
and vemurafenib group. The threshold for significance for the final overall survival analysis was a 
two-sided p value of less than 0·0499. The required number of deaths for the final overall survival 
analysis (n=250) was reached in August, 2015, and the data cutoff date for the final overall survival 
analysis was Aug 28, 2015, at which time 255 deaths had occurred. 
 
We did all efficacy analyses in the intention-to-treat population. We used the Kaplan-Meier method 
to estimate rates of progression-free survival and overall survival; a stratified log-rank test for 
treatment comparisons; an unstratified log-rank test for the subgroup analyses; and a Cox model to 
estimate the hazard ratio and corresponding 95% CI. We did non-stratified analyses for progression-
free survival and overall survival as sensitivity analyses. We assessed the proportional hazards 
assumption graphically by assessing the cumulative hazard function. The updated proportion of 
patients who achieved an overall response, and 95% CIs are reported for both treatment groups. We 
also used the Kaplan-Meier method to calculate medians and IQRs for duration of response. SAS 
version 9.2 was used for all analyses. 
 
Quality of life data were evaluable through to cycle 8 day 1, after which there were less than 25% of 
patients with baseline quality of life scores who remained enrolled in the vemurafenib group, which 
was too few patients to allow meaningful conclusions to be drawn. We assessed change from 
baseline in each domain score for each timepoint by treatment group using descriptive statistics. A 
change of score from baseline of greater than or equal to ten points was judged to be clinically 
meaningful, and formal statistical comparisons were not done. We did safety analyses on the safety 
population, which consisted of all patients who received at least one dose of study treatment. 
 
The effect of Ki67, pERK, and p56 biomarker expression on overall survival was analysed as a 
continuous variable and by comparing patients with expression above and below the median protein 
expression using Cox proportional hazards modelling. 
 
This study is registered with ClinicalTrials.gov, number NCT01689519. The study is closed to further 
enrolment, and patients already in the study will continue to be followed for long-term outcomes. 
 
Role of the funding source 
 
F Hoffmann-La Roche–Genentech funded, administered, and sponsored the study, which was 
designed by the academic authors in conjunction with Roche representatives. Data were collected 
by Roche and analysed in collaboration with the authors. The authors vouch for the accuracy and 
completeness of the data; YY, IC, JJH, MW, DOK, and IR had full access to all the raw data. JL, GAM, 
PAA, YY, IC, MW, DOK, and IR prepared the first draft of the report, and all authors contributed to 
subsequent drafts and made the decision to submit the report for publication. Editorial support was 
provided by ApotheCom (San Francisco, CA, USA), and was funded by F Hoffmann-La Roche–
Genentech. The corresponding author had full access to all the data and had final responsibility to 
submit for publication. 
 
Results 
Between Jan 8, 2013, and Jan 31, 2014, 1045 patients were screened, and 495 eligible patients with 
BRAFV600-mutant metastatic melanoma were randomly assigned to receive cobimetinib and 
vemurafenib (n=247) or placebo and vemurafenib (n=248; figure 1). The most common cause of 
screening failure was a negative test result for the BRAFV600 mutation. Baseline patient 
characteristics were generally well balanced between the two study groups (table 1).13 Of those 
patients in the cobimetinib and vemurafenib group who remained on treatment at 1 year, the mean 
of the cumulative doses of cobimetinib and vemurafenib delivered was 87·2% (SD 18·4) and 84·6% 
(19·8) of the starting doses, respectively, and for those patients who remained on treatment at 2 
years, the average of the cumulative doses delivered was 88·2% (SD 16·2) and 84·7% (19·7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Trial profileData cutoff Aug 28, 2015. Adapted with permission from Larkin and ... 
Figure 1.  
Trial profile 
Data cutoff Aug 28, 2015. Adapted with permission from Larkin and colleagues,13 with permission 
from the Massachusetts Medical Society. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. 
Baseline characteristics 
  Placebo and 
vemurafenib (n=248) 
Cobimetinib and 
vemurafenib (n=247) 
Age, years 55 (25–85) 56 (23–88) 
Sex 
 Men 140 (56%) 146 (59%) 
 Women 108 (44%) 101 (41%) 
Race 
 White 235 (95%) 227 (92%) 
 Other 13 (5%) 20 (8%) 
Geographical region 
 Australia/New Zealand/other 38 (15%) 40 (16%) 
 Europe 184 (74%) 182 (74%) 
 North America 26 (10%) 25 (10%) 
ECOG performance status* 
 0 164/244 (67%) 184/243 (76%) 
 1 80/243 (33%) 58/243 (24%) 
Metastatic status† 
 Unresectable stage IIIC 13 (5%) 21 (9%) 
 M1a 40 (16%) 40 (16%) 
 M1b 42 (17%) 40 (16%) 
 M1c 153 (62%) 146 (59%) 
Raised lactate dehydrogenase 
concentration‡ 
104/242 (43%) 112/242 (46%) 
History of brain metastases 2 (<1%) 1 (<1%) 
BRAF mutation subtype§ 
 V600E 174 (70%) 170 (69%) 
 V600K 32 (13%) 24 (10%) 
 Not done¶ 42 (17%) 53 (22%) 
Data are median (range) or n (%). ECOG=Eastern Cooperative Oncology Group. 
* 
One patient randomly assigned to the vemurafenib and cobimetinib group had performance 
status 2 at baseline (this was discovered after randomisation before the first dose was 
received). 
† 
The criteria of the American Joint Committee on Cancer for distant metastasis are as follows: 
M0=no detectable evidence of distant metastases; M1a=metastases to skin, subcutaneous 
tissue, or distant lymph nodes; M1b=metastases to lung; and M1c=metastases to all other 
visceral sites or distant metastases to any site combined with an increased serum lactate 
dehydrogenase concentration. 
‡§ 
After randomisation, we further characterised tumour DNA to identify specific V600 mutations 
using next-generation sequencing. 
¶ 
“Not done” refers to cases in which either no tumour sample was provided for mutation 
subtyping or sequencing could not be done on the tissue provided. 
 
 
 
An updated analysis of progression-free survival and response data (data cutoff on Jan 16, 2015) was 
done after a median follow-up of 14·2 months (IQR 8·5–17·3). The analysis of the cumulative hazard 
function showed that the proportional hazards assumption was not violated. The median duration of 
cobimetinib treatment for patients in the cobimetinib and vemurafenib group was 9·0 months (95% 
CI 8·1–10·2) and median duration of vemurafenib treatment for patients in this group was 9·2 
months (8·4–11·0). The median duration of vemurafenib treatment for patients in the vemurafenib 
and placebo group was 5·8 months (95% CI 5·5–7·4). 
 
Median investigator-assessed progression-free survival was significantly longer in patients treated 
with cobimetinib and vemurafenib than in those treated with vemurafenib and placebo (stratified 
analysis; figure 2A). Figure 3 shows the hazard ratios (HRs) for progression-free survival in different 
patient subgroups (unstratified analysis). Survival curves for patients with lactate dehydrogenase 
concentrations of the upper limit of normal or higher are shown in figure 2B, and those with lactate 
dehydrogenase concentrations below the upper limit of normal are in figure 2C. 
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Figure 2.  
Progression-free survival 
(A) Kaplan-Meier curve of progression-free survival in all patients. (B) Progression-free survival in 
patients with raised (greater than institutional upper limit of normal) baseline LDH levels and (C) 
normal LDH levels. Unstratified analysis. HR=hazard ratio. LDH=lactate dehydrogenase. 
 
 
 
 
 
Figure 3.  
Progression-free survival 
Prespecified subgroup analysis. Data cutoff Jan 16, 2015. NE=not estimable. ECOG=Eastern 
Cooperative Oncology Group. LDH=lactate dehydrogenase. *Unstratified analysis. 
 
 
 
 
 
 
 
 
At the data cutoff date of Jan 16, 2015, 172 (70%) of 247 patients in the cobimetinib and 
vemurafenib group had an objective response, compared with 124 (50%) of 248 in the vemurafenib 
group (appendix p 32, table 2). Most responses were seen by the time of the first tumour 
assessment at 8 weeks.13 Median duration of response was 13·0 months (95% CI 11·1–16·6) in the 
cobimetinib and vemurafenib group and 9·2 months (95% CI 7·5–12·8) in the vemurafenib plus 
placebo group. 84 (49%) of 172 patients in the cobimetinib plus vemurafenib group who had 
achieved a response progressed versus 73 (59%) of 124 patients in the vemurafenib plus placebo 
group. The median duration of response for patients who had achieved a complete response was 
18·1 months (95% CI 14·8–not estimable) in the cobimetinib and vemurafenib group and 16·9 
months (16·9–not estimable) in the placebo plus vemurafenib group. 
 
Table 2. 
Best response 
 Placebo and 
vemurafenib (n=248) 
Cobimetinib and 
vemurafenib (n=247) 
Complete response, n (%) 26 (10%) 39 (16%) 
Partial response, n (%) 98 (40%) 133 (54%) 
Stable disease, n (%) 92 (37%) 44 (18%) 
Progressive disease, n (%) 25 (10%) 19 (8%) 
Not done* 6 (2%) 12 (5%) 
Complete or partial response, n 
(%; 95% CI) 
124 (50%; 43·6–56·4) 172 (70%; 63·5–75·3) 
p value Reference <0·0001 
* 
Responses could not be assessed for patients who withdrew consent, were withdrawn by the 
site investigator, died, or started new anticancer therapy before the first tumour assessment. 
 
 
At the time of the protocol-specified final overall survival analysis (data cutoff Aug 28, 2015), median 
follow-up was 18·5 months (IQR 8·5–23·5). The combination of cobimetinib with vemurafenib 
significantly prolonged overall survival (stratified analysis; figure 4). The median overall survival for 
patients treated with cobimetinib and vemurafenib was 22·3 months (95% CI 20·3–not estimable) 
compared with 17·4 months (95% CI 15·0–19·8) for patients treated with vemurafenib (HR 0·70 [95% 
CI 0·55–0·90], p=0·005; figure 4A). 1-year overall survival was 74·5% (95% CI 68·9–80·2) in the 
cobimetinib and vemurafenib group and 63·8% (57·6–70·0) in the vemurafenib group; 2-year overall 
survival was 48·3% (41·4–55·2) and 38·0% (31·3–44·7), respectively. The HRs for overall survival in 
subgroups (unstratified analysis) are presented in figure 5. Survival curves for patients with lactate 
dehydrogenase concentrations at the upper limit of normal or higher are shown in figure 4B and 
those with lactate dehydrogenase concentrations below the upper limit of normal are in figure 4C. 
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Figure 4.  
Overall survival 
(A) Kaplan-Meier curve of overall survival in all patients. (B) Overall survival in patients with raised 
(greater than institutional upper limit of normal) baseline LDH levels and (C) normal LDH levels. Data 
cutoff Aug 28, 2015. HR=hazard ratio. LDH=lactate dehydrogenase. NE=not estimable. 
 
 
 
 
 
 
Figure 5.  
Overall survival 
Prespecified subgroup analysis. Data cutoff Aug 28, 2015. NE=not estimable. ECOG=Eastern 
Cooperative Oncology Group. *Unstratified analysis. 
 
Patients were followed up for subsequent anticancer therapy after progression (table 3). A similar 
proportion of patients received follow-up systemic therapy in each group; of those patients who 
received subsequent therapy, the most common type in both groups was immunotherapy (table 3). 
In most cases, the immunotherapeutic agent was ipilimumab (table 3). 
 
 
 
Table 3. 
Follow-up anticancer treatments§ in the intention-to-treat population (data cutoff Sept 30, 
2015) 
  Placebo and 
vemurafenib (n=213) 
Cobimetinib and 
vemurafenib (n=183) 
Patients with at least one treatment 125 (59%) 105 (57%) 
Any chemotherapy 37 (17%) 30 (16%) 
Any targeted therapy 36 (17%) 32 (18%) 
 BRAF inhibitor monotherapy 24 (11%) 19 (10%) 
 Combination of a BRAF and a 
MEK inhibitor* 
12 (6%) 15 (8%) 
 MEK inhibitor monotherapy 1 (1%) 2 (1%) 
Any immunotherapy 89 (42%) 67 (37%) 
 Ipilimumab monotherapy 80 (38%) 53 (29%) 
 Anti-PD-1/anti-PD-L1 
monotherapy 
35 (16%) 28 (15%) 
 Combination of ipilimumab and 
an anti-PD-1/PD-L1* 
4 (2%) 4 (2%) 
 Other† 1 (1%) 0 
Other treatment, including multiple 
lines‡ 
0 2 (1%) 
Data are n (%). PD-1=programmed death cell receptor 1. PD-L1=programmed death cell 
ligand 1. 
* 
Combination must have been administered in the same line of therapy. 
† 
Other immunotherapy agents included granulocyte colony-stimulating factor and adoptive 
immunotherapy. 
‡ 
Other types of therapy included corticosteroids and an unknown investigational product. 
§ 
Multiple uses of a type of therapy for an individual patient were only counted once in the 
frequency for that type of treatment; patients might have received multiple lines of treatment. 
 
Baseline expression levels of Ki67, pERK, and pS6 and their correlation with overall survival were 
assessed. Tissue availability was low in some cases; for 290, 319, and 325 patients, samples were 
evaluable for Ki67, pERK, and pS6, respectively (table 4, appendix p 33). In the vemurafenib plus 
placebo group, patients with high Ki67 expression (defined as being greater than the median) had 
shorter overall survival than patients who had low Ki67 expression (HR 1·45 [95% CI 0·94–2·25]). 
However, in the cobimetinib and vemurafenib group, there was no difference in overall survival for 
patients with high Ki67 compared with that in patients with low Ki67 (table 4). No association 
between protein expression (assessed by H-score) of pERK or pS6 and overall survival was noted in 
either treatment group (table 4). Additionally, the effect of the baseline expression of each marker 
on overall survival was assessed as a continuous variable, and the findings were consistent with the 
binomial analysis (appendix p 3). No interactions between treatment and biomarker subgroups were 
recorded; however, these analyses were limited by the small size of the biomarker subpopulations. A 
full analysis of all biomarkers assessed will form the basis of a secondary report. 
 
 
 
 Table 4. 
Overall survival by baseline biomarker status* (data cutoff Aug 28, 2015) 
 Placebo and vemurafenib 
(n=248) 
 
Cobimetinib and vemurafenib 
(n=247) 
 
Ki67 
>20% 66/140 
(47%) 
14·9 (9·5–
19·1) 
79/150 (53%) 21·6 (17·0–NE) 
≤20% 74/140 
(53%) 
19·8 (13·3–NE) 71/150 (47%) 21·5 (18·1–NE) 
HR of high vs low NA 1·45 (0·94–
2·25) 
NA 0·95 (0·60–1·49) 
pERK 
H-score >40 78/154 
(51%) 
14·9 (11·9–
22·7) 
81/165 (49%) NE (18·3–NE) 
H-score ≤40 76/154 
(49%) 
17·1 (12·6–
24·9) 
84/165 (51%) 21·1 (15·3–NE) 
HR of high vs low H-
score 
NA 1·09 (0·72–
1·66) 
NA 0·75 (0·48–1·17) 
pS6 
H-score >71 82/158 
(52%) 
19·1 (12·6–
24·9) 
80/167 (48%) 19·2 (16·2–NE) 
H-score ≤71 76/158 
(48%) 
15·4 (11·9–
20·5) 
87/167 (52%) 24·1 (18·3–NE) 
HR of high vs low H-
score 
NA 0·80 (0·53–
1·21) 
NA 1·14 (0·74–1·76) 
Data are n/N (%), median overall survival in months (95% CI) or HR (95% CI). NE=not 
estimable. HR=hazard ratio. NA=not applicable. 
* 
Biomarker status is based on population median. 
 
A total of 211 (85%) of 247 patients in the cobimetinib and vemurafenib group and 209 (85%) of 248 
in the vemurafenib group were eligible for quality of life analysis. Patients in the cobimetinib and 
vemurafenib group had similar quality of life compared with patients in the vemurafenib arm 
throughout the evaluable period (cycles 1–8; figure 6). 
 
 
Figure 6.  
EORTC QLQ-C30 global health status 
The dashed horizontal lines represent clinically meaningful change (≥10 point change from 
baseline) for improvement or deterioration in global health status. Error bars are standard 
errors of the mean. EORTC=European Organization for the Research and Treatment of 
Cancer. 
 
Updated safety data (data cutoff Sept 30, 2015) were consistent with those reported previously.13 
At the time of the safety data cutoff, median follow-up was 18·5 months (IQR 8·5–23·5) for patients 
in the cobimetinib and vemurafenib group, median duration of cobimetinib treatment was 9·0 
months (range 0·1–30·1), and median duration of vemurafenib treatment was 9·2 months (range 
0·3–30·3); for patients in the placebo and vemurafenib group, median duration of vemurafenib 
treatment was 5·8 months (range 0·2–29·3). For the patients in the cobimetinib and vemurafenib 
group who remained on treatment at 1 year, the mean dose of cobimetinib was 52 mg (SD 11) per 
day and the mean dose of vemurafenib was 1624 mg (381) per day; for those who remained on 
treatment at 2 years, the mean doses were 53 mg (SD 10) per day and 1627 mg (378) per day, 
respectively. 
 
Almost all patients in both groups had at least one adverse event, irrespective of association with 
treatment (table 5, appendix pp 4–27). Serious adverse events occurred in 92 patients (37%) in the 
cobimetinib and vemurafenib group and 69 patients (28%) in the vemurafenib group. Pyrexia (six 
patients [2%]) and dehydration (five patients [2%]) were the most common serious adverse events 
reported in the cobimetinib and vemurafenib group. All adverse events recorded in the study are 
reported in the appendix (pp 4–27). 
 
 
 
 
 
 
 
 
 
Table 5. 
Summary of adverse events in the safety population‡ (data cutoff Sept 30, 2015) 
 Placebo and 
vemurafenib (n=246) 
 
Cobimetinib and 
vemurafenib (n=247) 
 
 All grades Grade ≥3 All grades Grade ≥3 
Most common adverse events (occurring in ≥20% of patients in either group) 
Rash* 166 (68%) 40 (16%) 179 (73%) 42 (17%) 
Arthralgia 103 (42%) 12 (5%) 94 (38%) 6 (3%) 
Diarrhoea 82 (33%) 2 (1%) 150 (61%) 16 (7%) 
Fatigue 82 (33%) 7 (3%) 91 (37%) 11 (5%) 
Alopecia 75 (31%) 1 (<1%) 41 (17%) 1 (<1%) 
Hyperkeratosis 67 (27%) 6 (3%) 25 (10%) 1 (<1%) 
Nausea 64 (26%) 2 (1%) 105 (43%) 3 (1%) 
Pyrexia 59 (24%) 0 71 (29%) 3 (1%) 
Decreased appetite 50 (20%) 1 (<1%) 50 (20%) 0 
Photosensitivity reaction 48 (20%) 0 84 (34%) 8 (3%) 
Alanine aminotransferase 
concentration increase 
44 (18%) 15 (6%) 65 (26%) 28 (11%) 
γ-glutamyltransferase 
concentration increase 
44 (18%) 25 (10%) 54 (22%) 36 (15%) 
Vomiting 34 (14%) 2 (1%) 63 (26%) 4 (2%) 
Aspartate aminotransferase 
concentration increase 
31 (13%) 5 (2%) 60 (24%) 22 (9%) 
Serous retinopathy† 9 (4%) 0 67 (27%) 7 (3%) 
Blood creatine phosphokinase 
level increase 
7 (3%) 1 (<1%) 87 (35%) 30 (12%) 
Other selected adverse events (selected based upon known association with BRAF or 
MEK inhibition) 
Cutaneous squamous cell 
carcinoma 
31 (13%) 31 (13%) 10 (4%) 9 (4%) 
Keratoacanthoma 23 (9%) 21 (9%) 4 (2%) 3 (1%) 
Decreased ejection fraction 13 (5%) 3 (1%) 29 (12%) 5 (2%) 
QT prolongation 13 (5%) 3 (1%) 11 (5%) 3 (1%) 
Data are n (%). All adverse events are preferred terms. All events are presented irrespective 
of association with study drug. 
* 
Combined terms: includes (in decreasing order of reported incidence) the preferred terms 
rash, rash maculopapular, erythema, dermatitis acneiform, folliculitis, rash macular, rash 
papular, rash erythematous, acne, dermatitis, rash pruritic, furuncle, rash generalised, 
dermatitis allergic, rash follicular, rash pustular, dermatitis exfoliative, generalised erythema, 
rash morbilliform, and drug eruption. 
† 
Combined terms include (in decreasing order of reported incidence) the preferred terms 
chorioretinopathy, retinal detachment, detachment of retinal pigment epithelium, macular 
oedema, macular fibrosis, retinal disorder, retinopathy, subretinal fluid, and detachment of 
macular retinal pigment epithelium. 
‡ 
At the time of the primary analysis,13 eight patients randomly assigned to the placebo and 
vemurafenib group were believed to have received cobimetinib owing to site medication 
dispensing error and, therefore, were included in the cobimetinib and vemurafenib group. 
However, it was later established that seven of these eight patients did not in fact receive 
cobimetinib. These seven patients were reassigned to the placebo and vemurafenib group. 
Hence, for the safety population at the time of this update, relative to the original report of this 
study,13 the safety denominators for the two groups have changed from 254 to 247 for the 
cobimetinib and vemurafenib group and from 239 to 246 for the placebo and vemurafenib 
group. 
 
Adverse events judged to be related to study treatment were reported in 241 (98%) of 247 patients 
in the cobimetinib and vemurafenib group, with 147 (60%) of 247 patients experiencing a grade 3 or 
worse treatment-related event. In the vemurafenib group, 233 (95%) of 246 patients had treatment-
related adverse events, with 128 (52%) experiencing a grade 3 or worse treatment-related event. 
 
Regarding known vemurafenib-related adverse events, the frequency of cutaneous squamous cell 
carcinoma, keratoacanthoma, or Bowen's disease was lower in patients in the cobimetinib and 
vemurafenib group, occurring in 15 (6%) of 247 patients in this group compared with 48 (20%) of 
246 patients treated with vemurafenib. This finding is consistent with abrogation of paradoxical 
activation of the MAPK pathway. Similar to the primary analysis,13 photosensitivity was more 
common in the cobimetinib and vemurafenib group, occurring in 84 (34%) of 247 patients compared 
with 48 (20%) of 246 patients in the vemurafenib group. Most events in both groups were grade 1 or 
2 and were managed conservatively with topical medications; few patients required dose 
modifications. 
 
MEK inhibitor-specific adverse events in the cobimetinib and vemurafenib group included serous 
retinopathy, decreased left ventricular ejection fraction, and increased creatine phosphokinase level. 
 
Serous retinopathy of any grade occurred in 67 (27%) of 247 patients in the cobimetinib and 
vemurafenib group compared with nine (4%) of 246 patients in the vemurafenib group. Most of 
these events (60 [90%] of 67) were grade 1–2 (whereas seven events were grade 3 or worse), and 
the majority of patients maintained good visual acuity with conservative management (simple 
observation including counselling to the patient with monitoring under the care of an 
ophthalmologist and, where considered indicated by the ophthalmologist, interruption and/or dose 
reduction of one or both drugs). Seven patients in the cobimetinib and vemurafenib group had grade 
3 or worse serous retinopathy events, and five of these had resolved or were resolving by the time 
of the data cutoff. 
 
Decreased left ventricular ejection fraction grade 2 or worse occurred in 28 (11%) of 247 patients in 
the cobimetinib and vemurafenib group versus 12 (5%) of 246 patients in the vemurafenib group 
(appendix p 9). Most of these events were grade 2, with grade 3 events reported in five (2%) of 247 
patients in the cobimetinib and vemurafenib group and three (1%) of 246 patients in the 
vemurafenib plus placebo group. This adverse event was managed effectively according to study 
protocol with a dose reduction of cobimetinib, and no grade 4 event or death from this adverse 
event occurred. 
 
Elevated creatine phosphokinase level of grade 3 or worse occurred in 30 (12%) of 247 patients in 
the cobimetinib and vemurafenib group versus one (<1%) of 246 in the vemurafenib plus placebo 
group, respectively (see appendix p 9). Most cases were asymptomatic and managed conservatively 
with observation. 
 
The treatment regimen was discontinued in 52 (11%) of 493 patients overall because of treatment-
related adverse events, including 35 (14%) of 247 patients in the cobimetinib and vemurafenib group 
and 17 (7%) of 246 in the vemurafenib group. The most common reason for discontinuation of the 
regimen in the cobimetinib and vemurafenib group was aspartate aminotransferase increase (five 
patients [2%]) and in the vemurafenib plus placebo group was γ-glutamyltransferase level increase 
and fatigue (each in two patients [<1%]). 
 
In the cobimetinib and vemurafenib group, 87 (35%) patients had a dose reduction of vemurafenib 
as a result of adverse events, and 75 patients (30%) had a dose reduction of cobimetinib. In the 
placebo and vemurafenib group, 72 (29%) of 246 patients had a dose reduction of vemurafenib and 
27 (11%) had a dose reduction of placebo. 
 
Eight (2%) of 493 patients died during the study: five (2%) of 247 in the cobimetinib and vemurafenib 
group due to pneumonia, Clostridium difficile colitis, coma, cardiac arrest, and death (unspecified) 
and three (1%) of 246 in the vemurafenib group due to cardiac failure, atelectasis, and death 
(unspecified). 
 
Discussion 
This updated analysis of the coBRIM study, including more than a minimum of 1 year of follow-up, 
demonstrates a statistically significant and clinically meaningful improvement in median overall 
survival, progression-free survival, and the overall response in patients treated with the combination 
of cobimetinib and vemurafenib versus patients treated with vemurafenib plus placebo. Moreover, 
the estimated landmark 2-year overall survival shows sustained benefit of the combination of 
cobimetinib and vemurafenib versus vemurafenib plus placebo. The proportion of patients who 
achieved an overall response at the updated analysis were similar to those at the primary analysis; 
however, the proportions of patients achieving a complete response were higher at the updated 
analysis than at the primary analysis (in the cobimetinib and vemurafenib group, an increase from 25 
[10%] of 247 at the primary analysis to 39 [16%] of 247 in the updated analysis, and in the 
vemurafenib group an increase to 26 [11%] of 248 from 11 [4%] of 248), indicating that some 
patients had an improved response with continued treatment. The safety profile remained 
consistent with that at the time of the primary analysis13 and quality of life was maintained. 
 
The HRs for overall survival favoured the cobimetinib and vemurafenib group compared with 
vemurafenib in most prespecified patient subgroups assessed, including those with key prognostic 
clinical characteristics (ECOG performance status ≥1 vs 0, raised lactate dehydrogenase 
concentration, and advanced stage of disease). Of the MEK inhibitor–BRAF inhibitor phase 3 
combination studies done so far, coBRIM enrolled the highest proportion of patients with raised 
baseline lactate dehydrogenase concentrations, who represent a distinct population with poorer 
prognosis 3; 4; 5; 6; 16; 17; 22; 23; 24 ;  25 than those with normal lactate dehydrogenase levels. As 
expected, patients with raised lactate dehydrogenase concentrations had shorter median survival 
than those with normal lactate dehydrogenase concentrations in both the cobimetinib and 
vemurafenib and the vemurafenib groups. Patients with normal lactate dehydrogenase 
concentrations, who are often considered for therapeutic options other than BRAF or MEK-targeted 
therapies, might benefit from long-term disease control with the combination of cobimetinib and 
vemurafenib. The treatment effect was similar in patients irrespective of the BRAF mutation of their 
tumour (BRAFV600E or BRAFV600K), which is consistent with previous reports concerning 
vemurafenib monotherapy.5 
 
These data are in line with a recent long-term follow-up (median 21 months) of BRAF inhibitor-naive 
patients receiving cobimetinib and vemurafenib enrolled in the BRIM-7 phase 1 study12 which 
reported 87·3% (95% CI 76·7–94·4) of patients achieving an overall response, median progression-
free survival of 13·8 months (95% CI 10·1–20·6), and median overall survival of 28·5 months (23·3–
34·6) with 2-year overall survival of 61% (95% CI 47·8–74·4).26 
 
Global health status score seemed to decrease at treatment cycle 8 for patients in the vemurafenib 
plus placebo group. The cycle 8 visit is the closest measure of quality of life to the timepoint at which 
median progression-free survival for patients enrolled in the vemurafenib group is reached (7·2 
months), and thus this decrease in global health status score probably represents a decrease in 
quality of life that corresponds to disease progression. 
 
Cobimetinib and vemurafenib were well tolerated and continued to show an acceptable and 
manageable safety profile compared with vemurafenib plus placebo; no new safety concerns were 
identified with longer follow-up. Compared with the primary analysis,13 the incidence of rash in the 
cobimetinib and vemurafenib group was nearly identical (101 [41%] of 247 vs 99 [39%] of 254) and 
was slightly higher in the vemurafenib plus placebo group (94 [38%] of 246 vs 85 [36%] of 239). Most 
adverse events were grade 1 or 2 and were effectively managed with supportive therapy and dose 
modifications. No specific adverse events necessitated withdrawal of the study regimen in more 
than 2% of patients. We have previously shown that most cobimetinib and vemurafenib-related 
adverse events occur early in the course of treatment (within the first 28 days for grade 3 or worse 
adverse events) and are mild or moderate, monitorable, and manageable by dose modification and 
supportive care. 27 Although tolerability of the phase 3 dose (and subsequent commercial dose) was 
determined based on the phase 1–2 BRIM-7 study,12 the regimen remained tolerable in the phase 3 
study. 
 
As expected, known MEK inhibitor-related adverse events, including serous retinopathy, decreased 
left ventricular ejection fraction, and increased creatine phosphokinase concentration, were more 
common in the cobimetinib and vemurafenib group compared with the vemurafenib plus placebo 
group but were generally mild or moderate and manageable. Most serous retinopathy events were 
grade 1–2 in severity, and most patients maintained good visual acuity with observation. Similarly, 
most decreased left ventricular ejection fraction events were grade 2, with no grade 4 events or 
deaths, and this event was effectively managed by adherence to protocol guidelines. Increased 
creatine phosphokinase level was typically asymptomatic and managed by observation. 
 
Although photosensitivity, a known vemurafenib-related adverse event, also occurred more 
commonly in the cobimetinib and vemurafenib group, most events were grade 1 and 2 and no grade 
4 events or deaths due to photosensitivity occurred. Proactive patient education, training of clinical 
staff, and ongoing management of expected adverse events is important to reduce the effect of 
photosensitivity. 
 
The coBRIM study also assessed several molecular markers (Ki67, pERK, and pS6) in the baseline 
tumour samples for effect on survival and for interaction with the treatment groups. These markers 
were analysed to assess the potential effect of proliferative state (Ki67), MAPK activation (pERK), 
and pS6 (PI3K–MAPK downstream effector) on survival outcomes. High Ki67 expression at baseline 
was associated with a shorter median overall survival in the vemurafenib group but did not affect 
overall survival in the combination cobimetinib and vemurafenib group. This finding might be a 
result of baseline Ki67 level being indicative of activity of the BRAF–MEK–ERK pathway and the 
ability of vemurafenib combined with cobimetinib to more effectively inhibit the pathway than 
vemurafenib alone.28 Despite substantial variety in the staining score between individual patients, 
no associations were recorded between pERK and pS6 H-score and clinical outcome, which might be 
indicative of technical limitations of use of immunohistochemical analyses to quantify the output of 
these molecular pathways or of other factors that over-ride these signals. Although these are 
retrospective exploratory analyses that require validation, the results suggest that survival outcomes 
of combined BRAF and MEK inhibition might not be affected by the status of tumour cell signalling at 
baseline. 
 
Comparison of the updated coBRIM data with the other phase 3 combination MEK inhibitor and 
BRAF inhibitor studies16; 17 ;  18 is not feasible because of study differences such as baseline 
patient population characteristics, crossover of patients from the placebo group to the combination 
group with disease progression (which was not allowed in coBRIM), and availability of ongoing 
treatment beyond progression with study drugs in case of limited progression of disease (also not 
permitted in coBRIM). Nevertheless, the overall efficacy data of the combination of cobimetinib and 
vemurafenib was similar to that of two randomised phase 3 trials; these studies compared the 
combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib with dabrafenib 
(COMBI-d)16 ;  17 and dabrafenib and trametinib with vemurafenib (COMBI-v).18 However, this 
observation can only be confirmed with a head-to-head clinical study of the combinations, which 
would address the potential confounding factors described previously. 
 
In conclusion, patients treated with the combination of cobimetinib and vemurafenib achieved a 
higher objective response, longer progression-free survival, and longer overall survival compared 
with patients treated with vemurafenib alone. HRs favoured most prespecified clinical and molecular 
subgroups assessed, and there were no differences in quality of life scores between the two groups. 
Safety was consistent with that previously reported.12; 13 ;  26 The combination of cobimetinib and 
vemurafenib was recently approved by the US Food and Drug Administration29 ;  30 and the 
European Medicines Agency31 ;  32 for the treatment of advanced BRAFV600-mutant melanoma 
and represents a new standard of treatment for patients with this disease. 
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